Post #98: Bigger and better biotech

2020 has been the year when we have all used with unfortunate regularity terms such as antibodies, asymptomatic, placebo, vaccine and more. Although the tragic cost of COVID-19 continues to be counted, the virus has at least succeeded in shining a huge spotlight on the biotech industry. With growing investor and public interest in the sector, we were lucky enough to hear the views of four experts within the field (three of whom had Doctorates) at a webinar yesterday.

Similar to how the pandemic has accelerated digital adoption in areas such as online retail and payment, one of yesterday’s speakers (Dr Barbara Domayne-Hayman, an entrepreneur who began her career at Astra Zeneca) described how recent collaboration across the biotech industry had “done in ten months what normally takes ten years.” Interestingly, while big pharma (not just Astra, but also, say, Pfizer) have scaled up vaccination projects, much of the grassroots innovation with regard to understanding and solving COVID-19 occurred at an academic and/or biotech level. The legacy of such a partnership approach should be enduring when it comes to finding cures for other viruses, per the consensus among the speakers.

When the panellists were asked about what would be ‘the next big thing’ for the industry, two clear themes emerged: the digitalisation of the healthcare industry and innovation with regard to dementia.With regard to the former, it was described as “an unstoppable movement” (by Dr Andy Richards CBE, a biotech entrepreneur and investor). Look out for developments across a broad spectrum which encompasses healthcare monitoring, rehabilitation and telemedicine. Turning to dementia and diseases more broadly affecting the brain, this will matter increasingly, particularly as populations age. Separately, we were pleased to note that Novo Nordisk announced yesterday that one of its drugs had entered phase three trials for Alzheimer’s disease.

One final consideration, or perhaps the $64,000 question, is what should investors look for if they want involvement in the sector. Spoiler alert: there is no single answer, but the panellists asserted that quality management was key – we concur. With biotech specifically, it is integral to understand exactly what problems companies are trying to solve and whether they are even worth solving in the first place (in terms of cost-benefit). Our approach to the sector also involves trying to think laterally, looking to businesses involved in the value chain, particularly in terms of life sciences tools and equipment.

The above does not constitute investment advice and is the sole opinion of the author at the time of publication. Heptagon Capital is an investor in Novo Nordisk. The author of this piece has no personal direct investment in the business. Past performance is no guide to future performance and the value of investments and income from them can fall as well as rise.​​​​​​​

Alex Gunz, Fund Manager


The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document. 

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital's prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital's prior written consent. 

Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email [email protected] 

Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority 

Related Insights

Featured Insights
Featured Insights20 January 2021

Season 3, Post 3: Shop online, and help save the planet

Several times a day, it seems, the doorbell rings, the dog barks and yet another package is delivered to the Gunz household. This pattern – exacerbated under lockdown – is being repeated up and down the country and across much of the world. While the speed and convenience of online ordering is certainly desirable, a […]

Learn more
Featured Insights
Featured Insights15 January 2021

Season 3, Post 2: Hot topics in healthcare

The Westin St Francis hotel on Union Square in downtown San Francisco is normally where the great and good of the healthcare world descend during the second week of January. This year, of course, is far from normal and one of the industry’s largest conferences (organised by JP Morgan and now in its 39th year) […]

Learn more
Featured Insights
Featured Insights06 January 2021

Season 3, Post 1: The weird and wonderful

Welcome to 2021. Sign of the times perhaps, but the title for our opening Blog post of the year perhaps captures both our current and future assessment of the world. Uncertainty reigns as the pandemic rages, but this won’t stop dynamic innovation occurring across all industries. With the present so murky, what could be more […]

Learn more

Get The Updates

Separated they live in Bookmarks right at the coast of the famous Semantics, large language ocean Separated they live in Bookmarks right